Krenning E - Search Results

1

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.

Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Konijnenberg M, et al. Among authors: krenning e. J Nucl Med. 2007 Jan;48(1):134-42. J Nucl Med. 2007. PMID: 17204710 Free article.

2

New advances in peptide receptor radionuclide therapy.

de Jong M, Krenning E. de Jong M, et al. Among authors: krenning e. J Nucl Med. 2002 May;43(5):617-20. J Nucl Med. 2002. PMID: 11994523 Free article. No abstract available.

3

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Rolleman EJ, et al. Eur J Nucl Med Mol Imaging. 2010 May;37(5):1018-31. doi: 10.1007/s00259-009-1282-y. Epub 2009 Nov 14. Eur J Nucl Med Mol Imaging. 2010. PMID: 19915842 Review.

4

Preclinical and clinical studies of peptide receptor radionuclide therapy.

Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, Valkema R, Kwekkeboom DJ, de Jong M. Pool SE, et al. Among authors: krenning ep. Semin Nucl Med. 2010 May;40(3):209-18. doi: 10.1053/j.semnuclmed.2009.12.001. Semin Nucl Med. 2010. PMID: 20350630 Review.

5

Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.

Melis M, de Swart J, de Visser M, Berndsen SC, Koelewijn S, Valkema R, Boerman OC, Krenning EP, de Jong M. Melis M, et al. J Nucl Med. 2010 Dec;51(12):1962-8. doi: 10.2967/jnumed.110.080143. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078795 Free article.

6

Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.

Melis M, Valkema R, Krenning EP, de Jong M. Melis M, et al. J Nucl Med. 2012 May;53(5):749-53. doi: 10.2967/jnumed.111.098665. Epub 2012 Apr 10. J Nucl Med. 2012. PMID: 22496587 Free article.

7

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Valkema R, et al. Semin Nucl Med. 2002 Apr;32(2):110-22. doi: 10.1053/snuc/2002.31025. Semin Nucl Med. 2002. PMID: 11965606 Clinical Trial.

8

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. De Jong M, et al. Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.

9

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Capello A, et al. J Nucl Med. 2003 Jan;44(1):98-104. J Nucl Med. 2003. PMID: 12515882 Free article.

10

Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.

De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, Burggraaf JD, Körner M, Reubi JC, Krenning EP. De Jong M, et al. J Nucl Med. 2004 Jul;45(7):1168-71. J Nucl Med. 2004. PMID: 15235063 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

515 results

Search Page

Filters